drugset
drugset / Trial / NCT06285591

Lactobacillus Reuteri Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors

NCT06285591 ↗

Phase 2 Completed 160 enrolled West China Hospital
RandomizedParallel-groupQuadruple-blindPrevention

Summary

To evaluate the efficacy and safety of Lactobacillus reuteri for prevention and treatment of oral mucositis in patients undergoing radiotherapy for malignant head and neck tumors.

Timeline

Start
2024-03-01
Primary completion
2025-01-01
Completion
2025-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lactobacillus reuteri Other / unclassified 2e+08 cells Oral

Indications

head and neck cancer